Literature DB >> 17142200

Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride.

Jess T Whitson1, H Dwight Cavanagh, Neema Lakshman, W Matthew Petroll.   

Abstract

The corneal toxicity of 2 intraocular pressure-lowering agents was compared in a rabbit cornea model with New Zealand White rabbits. Corneal epithelial morphology and cell size were assessed by in vivo confocal microscopy. Baseline microscopic examinations were performed on 1 eye of each animal. Two weeks later, the eyes were bathed for 3 min in travoprost 0.004% preserved without benzalkonium chloride (BAK( or latanoprost 0.005% preserved with 0.02% BAK; the eyes were then rinsed with balanced salt solution, and the corneas were again examined by confocal microscopy (n=4/group). A second group of animals was exposed to the medications through a dosing regimen of 1 drop/min (lpar3 drops total) (n=4/group). In eyes treated with travoprost without BAK (3-min bath), superficial epithelial cells were similar to baseline, as indicated by their visible cell borders and bright nuclei. In contrast, the surface cells in eyes treated with latanoprost were significantly smaller and brighter and had less distinct borders. Surface cell size was significantly smaller as compared with baseline size and as compared with rabbits treated with travoprost without BAK for 3 min. Similar effects on corneal epithelial cell morphology were observed with the 1-drop/min dosing regimen. In this rabbit model, travoprost 0.004% preserved without BAK did not cause corneal epithelial toxicity; latanoprost 0.005% induced superficial cell loss, most likely caused by the presence of a relatively high concentration of BAK (0.02%).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17142200     DOI: 10.1007/bf02850305

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  20 in total

Review 1.  Benzalkonium Chlorides: Uses, Regulatory Status, and Microbial Resistance.

Authors:  Beatriz Merchel Piovesan Pereira; Ilias Tagkopoulos
Journal:  Appl Environ Microbiol       Date:  2019-06-17       Impact factor: 4.792

2.  Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients.

Authors:  M Figus; M Nardi; P Piaggi; M Sartini; G Guidi; L Martini; S Lazzeri
Journal:  Eye (Lond)       Date:  2014-01-17       Impact factor: 3.775

3.  Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model.

Authors:  Su Khoh-Reiter; Bart A Jessen
Journal:  BMC Ophthalmol       Date:  2009-07-28       Impact factor: 2.209

4.  Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients.

Authors:  Michael B Horsley; Malik Y Kahook
Journal:  Clin Ophthalmol       Date:  2009-06-02

5.  First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results.

Authors:  Jordana K Schmier; David W Covert
Journal:  Clin Ophthalmol       Date:  2010-05-14

6.  Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits.

Authors:  Abayomi B Ogundele; Guangming Li; Joel J Ellis
Journal:  Clin Ophthalmol       Date:  2010-02-18

7.  In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%.

Authors:  Abayomi B Ogundele; David Earnest; Marsha A McLaughlin
Journal:  Clin Ophthalmol       Date:  2010-07-30

8.  Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost.

Authors:  Gregory Katz; Clark L Springs; E Randy Craven; Michela Montecchi-Palmer
Journal:  Clin Ophthalmol       Date:  2010-11-03

9.  Analysis of the effects of preservative-free tafluprost on the tear proteome.

Authors:  Sebastian Funke; Sabine Beck; Katrin Lorenz; Marion Kotterer; Dominik Wolters; Natarajan Perumal; Norbert Pfeiffer; Franz H Grus
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

10.  Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: an in vivo toxicity assay.

Authors:  Hong Liang; Christophe Baudouin; Marie-Odile Faure; Grégory Lambert; Françoise Brignole-Baudouin
Journal:  Mol Vis       Date:  2009-08-25       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.